Alkaline phosphatase (alkaline phosphatase; Apase)   中文名称: 碱性磷酸酶

[1]. Alkaline Phosphatase: An Overview. Indian J Clin Biochem. 2014 Jul; 29(3): 269-278.

[2]. The role of alkaline phosphatase in intracellular lipid accumulation in the human hepatocarcinoma cell line, HepG2. Exp Mol Pathol. 2017 Apr;102(2):224-229.

Alkaline phosphatase (AP) is an oral medication with very few side effects. AP acts only locally in the colon, reducing persistent colonic inflammation caused by Gram-negative bacterial endotoxins and extracellular ATP in patients with ulcerative colitis (UC). AP is an enzyme that catalyzes the conversion of orthophosphate monoesters and water into alcohols and orthophosphates. EC 3.1.3.1. Indications: It has been studied for the treatment of ulcerative colitis. Mechanism of Action: Gram-negative bacterial endotoxins (LPS) and adenosine triphosphate (ATP) are two substrates that can disrupt organ homeostasis. Studies have shown that the dephosphorylation of LPS and extracellular ATP by AP can reduce inflammation-induced damage, thereby restoring homeostasis in target organs such as the gastrointestinal tract and kidneys. In the gastrointestinal tract, the main source of LPS is colonized Gram-negative microorganisms. The colonic mucosal surface of patients with ulcerative colitis (UC) is characterized by intermittent damage and increased permeability due to chronic inflammation. The consequences of intestinal mucosal damage include decreased alkaline phosphatase (AP) levels and increased infiltration of LPS-reactive cells, thereby maintaining the inflammatory response. In the gastrointestinal tract, the primary source of LPS is colonized Gram-negative microorganisms. AP alleviates LPS-mediated inflammation by inhibiting intestinal epithelial cell activation and preventing systemic inflammatory responses caused by endotoxin leakage through the inflamed intestinal mucosa with increased permeability.

496.275

9001-78-9

18985873

White to off-white solid powder

1.12 g/mL at 20 °C

1.41 °C

-5

227

6

8

11

35

846

0

O=C(C1CCCN1C(C(C)N)=O)NCC(N1CCCC1C(NC(C(=O)O)CCC/N=C(\N)/N)=O)=O

ITZMJCSORYKOSI-UHFFFAOYSA-N

InChI=1S/C21H36N8O6/c1-12(22)19(33)29-10-4-6-14(29)17(31)26-11-16(30)28-9-3-7-15(28)18(32)27-13(20(34)35)5-2-8-25-21(23)24/h12-15H,2-11,22H2,1H3,(H,26,31)(H,27,32)(H,34,35)(H4,23,24,25)

2-[[1-[2-[[1-(2-aminopropanoyl)pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

H2O :~100 mg/mL

配方 1 中的溶解度: 50 mg/mL (Infinity mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。